Polar Asset Management Partners Inc. Trims Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)

Polar Asset Management Partners Inc. decreased its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 67.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,700 shares of the company’s stock after selling 150,700 shares during the period. Polar Asset Management Partners Inc. owned approximately 0.07% of Acelyrin worth $353,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of SLRN. Principal Financial Group Inc. bought a new stake in Acelyrin during the 2nd quarter valued at approximately $49,000. HighTower Advisors LLC purchased a new stake in Acelyrin in the third quarter worth $50,000. SG Americas Securities LLC bought a new position in Acelyrin in the second quarter worth $51,000. Nisa Investment Advisors LLC lifted its position in Acelyrin by 58,570.8% during the second quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company’s stock valued at $62,000 after buying an additional 14,057 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Acelyrin during the 3rd quarter valued at $77,000. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wells Fargo & Company boosted their price objective on shares of Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. Piper Sandler reduced their price objective on Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Morgan Stanley dropped their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Monday, August 19th. Finally, HC Wainwright raised their price target on Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $11.40.

Acelyrin Trading Up 1.0 %

Shares of SLRN opened at $4.25 on Friday. The business’s fifty day simple moving average is $5.30 and its two-hundred day simple moving average is $5.01. Acelyrin, Inc. has a 12 month low of $3.36 and a 12 month high of $8.89.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.